The Efficacy of Olanzapine/Samidorphan on Negative Symptoms
The Journal of Clinical Psychiatry · 2026
DOI: 10.4088/jcp.25m16170 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Clinical Psychiatry, 2026. Verfasst von Roger S McIntyre und 4 weiteren Autor:innen. Beteiligte Einrichtung: Alkermes, Inc, Waltham, Massachusetts. Hauptthemen laut MEDLINE: Antipsychotic Agents, Naltrexone, Narcotic Antagonists, Olanzapine. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Alkermes, Inc, Waltham, Massachusetts.
- Corresponding Author: Christina Arevalo, MS, Alkermes, Inc, 900 Winter St, Waltham, MA 02451-1420 (christina.arevalo@alkermes.com).
- Alkermes Pharma Ireland Ltd, Dublin, Ireland.
- Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, New York.
- Department of Psychiatry and Molecular Medicine Hempstead, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
- The Feinstein Institute for Medical Research, Center for Psychiatric Neuroscience, Northwell Health, New Hyde Park, New York.
Zitieren
APA
McIntyre, R. S., Matthews, D. M., Arevalo, C., McDonnell, D., & Correll, C. U. (2026). The Efficacy of Olanzapine/Samidorphan on Negative Symptoms. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.25m16170
Vancouver
McIntyre RS, Matthews DM, Arevalo C, McDonnell D, Correll CU. The Efficacy of Olanzapine/Samidorphan on Negative Symptoms. The Journal of Clinical Psychiatry. 2026. doi:10.4088/jcp.25m16170
BibTeX
@article{McIntyre2026,
author = {McIntyre, Roger S and Matthews, Desiree M and Arevalo, Christina and McDonnell, David and Correll, Christoph U},
title = {The Efficacy of Olanzapine/Samidorphan on Negative Symptoms},
journal = {The Journal of Clinical Psychiatry},
year = {2026},
doi = {10.4088/jcp.25m16170}
}
EUVIMED